Skandinaviska Enskilda Banken AB publ Increases Holdings in BridgeBio Pharma, Inc. $BBIO

Skandinaviska Enskilda Banken AB publ lifted its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 152.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 148,917 shares of the company’s stock after purchasing an additional 89,856 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in BridgeBio Pharma were worth $7,735,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in shares of BridgeBio Pharma by 2.1% during the 3rd quarter. Vanguard Group Inc. now owns 16,832,059 shares of the company’s stock worth $874,257,000 after purchasing an additional 347,074 shares during the last quarter. Geode Capital Management LLC lifted its stake in BridgeBio Pharma by 5.1% in the second quarter. Geode Capital Management LLC now owns 3,681,580 shares of the company’s stock valued at $158,991,000 after purchasing an additional 178,686 shares during the last quarter. Invesco Ltd. grew its holdings in BridgeBio Pharma by 27.0% during the second quarter. Invesco Ltd. now owns 2,801,065 shares of the company’s stock valued at $120,950,000 after purchasing an additional 594,902 shares during the period. Norges Bank purchased a new stake in BridgeBio Pharma in the second quarter worth $84,488,000. Finally, Principal Financial Group Inc. raised its stake in shares of BridgeBio Pharma by 23.0% in the third quarter. Principal Financial Group Inc. now owns 1,267,412 shares of the company’s stock valued at $65,829,000 after buying an additional 236,885 shares during the period. Institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma News Summary

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Strong Phase 3 PROPEL‑3 achondroplasia results improve the program’s regulatory and commercial outlook — a clear fundamental catalyst supporting upside for BBIO. Read More.
• Positive Sentiment: HC Wainwright raised near‑term EPS estimates and bumped its price target to $100 while keeping a Buy rating — analyst upgrades can lift sentiment and buying interest. Read More.
• Neutral Sentiment: Upcoming Q4/2025 earnings and Feb. 24 conference call create a scheduled event risk: results and program/cash‑burn details could drive short‑term volatility either way. Read More.
• Neutral Sentiment: Company granted inducement RSUs to new hires (76,701 shares) — modest ongoing dilution to monitor but not a large immediate overhang. Read More.
• Neutral Sentiment: Small institutional buying: Oppenheimer reported a new 7,845‑share stake per 13F filing — signals some investor interest but immaterial scale. Read More.
• Negative Sentiment: Clustered insider selling on Feb. 17: Director Randal Scott sold 10,000 shares (~$754k) and the CFO sold 13,600 shares (~$1.02M), alongside other officer sales — concentrated disposals are pressuring near‑term sentiment. Read More.
• Negative Sentiment: Smaller CAO sale (510 shares) and a pattern of executive liquidity events — repeated sales by insiders can keep downward pressure until management rebuilds conviction via buying or other signals. Read More.
• Neutral Sentiment: Reported short‑interest data is inconsistent (entries show zero shares / NaN) and does not currently indicate a material short‑squeeze dynamic — treat the short‑interest note as noise until clearer reporting emerges.

BridgeBio Pharma Stock Performance

Shares of NASDAQ:BBIO opened at $70.72 on Friday. BridgeBio Pharma, Inc. has a 52-week low of $28.33 and a 52-week high of $84.94. The firm has a fifty day moving average of $75.66 and a 200 day moving average of $63.84. The firm has a market capitalization of $13.63 billion, a PE ratio of -16.92 and a beta of 1.13.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on BBIO shares. Piper Sandler lifted their price objective on BridgeBio Pharma from $93.00 to $98.00 and gave the stock an “overweight” rating in a report on Thursday, October 30th. Wells Fargo & Company lifted their target price on shares of BridgeBio Pharma from $88.00 to $98.00 and gave the stock an “overweight” rating in a research note on Friday, February 13th. TD Cowen restated a “buy” rating on shares of BridgeBio Pharma in a research note on Monday, January 12th. HC Wainwright raised their price objective on shares of BridgeBio Pharma from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Morgan Stanley started coverage on shares of BridgeBio Pharma in a report on Tuesday, January 6th. They set an “overweight” rating and a $96.00 target price on the stock. Twenty-two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $82.05.

Insider Transactions at BridgeBio Pharma

In other BridgeBio Pharma news, CAO Maricel Apuli sold 510 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $74.31, for a total value of $37,898.10. Following the completion of the sale, the chief accounting officer owned 123,945 shares in the company, valued at approximately $9,210,352.95. The trade was a 0.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Thomas Trimarchi sold 13,600 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $74.72, for a total transaction of $1,016,192.00. Following the sale, the chief financial officer owned 336,585 shares of the company’s stock, valued at $25,149,631.20. This represents a 3.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 176,121 shares of company stock worth $13,009,631. 18.20% of the stock is currently owned by company insiders.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.